Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
- Authors:
- Bixian Chen
- Jing Guo
- Hongmei Ye
- Xinyu Wang
- Yufei Feng
-
Affiliations: Department of Pharmacy, Peking University People's Hospital, Beijing 100044, P.R. China, Clinical Trial Institution, Peking University People's Hospital, Beijing 100044, P.R. China - Published online on: March 11, 2024 https://doi.org/10.3892/mmr.2024.13197
- Article Number: 73
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Cohn JN, Ferrari R and Sharpe N: Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 35:569–582. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Yang D, Liu HQ, Liu FY, Tang N, Guo Z, Ma SQ, An P, Wang MY, Wu HM, Yang Z, et al: The roles of noncardiomyocytes in cardiac remodeling. Int J Biol Sci. 16:2414–2429. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu QQ, Xiao Y, Yuan Y, Ma ZG, Liao HH, Liu C, Zhu JX, Yang Z, Deng W and Tang QZ: Mechanisms contributing to cardiac remodelling. Clin Sci (Lond). 131:2319–2345. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gao J, Xu W, Wang J, Wang K and Li P: The role and molecular mechanism of non-coding RNAs in pathological cardiac remodeling. Int J Mol Sci. 18:6082017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang LS, Liu Y, Chen Y, Ren JL, Zhang YR, Yu YR, Jia MZ, Ning ZP, Du J, Tang CS and Qi YF: Intermedin alleviates pathological cardiac remodeling by upregulating klotho. Pharmacol Res. 159:1049262020. View Article : Google Scholar : PubMed/NCBI | |
|
Takefuji M, Wirth A, Lukasova M, Takefuji S, Boettger T, Braun T, Althoff T, Offermanns S and Wettschureck N: G(13)-mediated signaling pathway is required for pressure overload-induced cardiac remodeling and heart failure. Circulation. 126:1972–1982. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
McCarroll CS, He W, Foote K, Bradley A, McGlynn K, Vidler F, Nixon C, Nather K, Fattah C, Riddell A, et al: Runx1 deficiency protects against adverse cardiac remodeling after myocardial infarction. Circulation. 137:57–70. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, Wang XF and Frangogiannis NG: Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation. 116:2127–2138. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ni L, Yuan C, Chen G, Zhang C and Wu X: SGLT2i: Beyond the glucose-lowering effect. Cardiovasc Diabetol. 19:982020. View Article : Google Scholar : PubMed/NCBI | |
|
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M and McMurray JJV; RECORD Study Team, : Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet. 373:2125–2135. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wilcox T, De Block C, Schwartzbard AZ and Newman JD: Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar. J Am Coll Cardiol. 75:1956–1974. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373:2117–2128. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M and Matthews DR; CANVAS Program Collaborative Group, : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 377:644–657. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 380:347–357. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, et al: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 42:3599–3726. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al: 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 145:e895–e1032. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Braunwald E: Gliflozins in the management of cardiovascular disease. N Engl J Med. 386:2024–2034. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Van Steenbergen A, Balteau M, Ginion A, Ferté L, Battault S, Ravenstein CM, Balligand JL, Daskalopoulos EP, Gilon P, Despa F, et al: Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep. 7:411662017. View Article : Google Scholar : PubMed/NCBI | |
|
Cowie MR and Fisher M: SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 17:761–772. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, Alber H, Berger R, Kaulfersch C, Leitner K, et al: Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-the EMMY trial. Am Heart J. 221:39–47. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
von Lewinski D, Tripolt NJ, Sourij H, Pferschy PN, Oulhaj A, Alber H, Gwechenberger M, Martinek M, Seidl S, Moertl D, et al: Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial)-a phase III study. Am Heart J. 246:152–160. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, et al: Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 143:516–525. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Aimo A, Vergaro G, González A, Barison A, Lupón J, Delgado V, Richards AM, de Boer RA, Thum T, Arfsten H, et al: Cardiac remodelling-part 2: Clinical, imaging and laboratory findings. A review from the study group on biomarkers of the heart failure association of the European society of cardiology. Eur J Heart Fail. 24:944–958. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Singh JSS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG, Pearson ER, Struthers AD and Lang CC: Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 15:972016. View Article : Google Scholar : PubMed/NCBI | |
|
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, et al: Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 77:243–255. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, et al: Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART cardiolink-6 randomized clinical trial. Circulation. 140:1693–1702. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L, Poulsen MK, Tuxen CD, Möller S, Gustafsson F, et al: Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: A substudy of the empire HF randomized clinical trial. JAMA Cardiol. 6:836–840. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hwang IC, Cho GY, Yoon YE, Park JJ, Park JB, Lee SP, Kim HK, Kim YJ and Sohn DW: Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc Diabetol. 19:692020. View Article : Google Scholar : PubMed/NCBI | |
|
Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T and Hirata KI: Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 17:1322018. View Article : Google Scholar : PubMed/NCBI | |
|
Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD and Lang CC: A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: The DAPA-LVH trial. Eur Heart J. 41:3421–3432. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lan NSR, Yeap BB, Fegan PG, Green G, Rankin JM and Dwivedi G: Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes. Int J Cardiovasc Imaging. 37:517–527. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, Alber H, Berger R, Lichtenauer M, Saely CH, et al: Empagliflozin in acute myocardial infarction: The EMMY trial. Eur Heart J. 43:4421–4432. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ersbøll M, Jürgens M, Hasbak P, Kjær A, Wolsk E, Zerahn B, Brandt-Jacobsen NH, Gæde P, Rossing P, Faber J, et al: Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: The SIMPLE randomized clinical trial. Int J Cardiovasc Imaging. 38:579–587. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Palmiero G, Cesaro A, Galiero R, Loffredo G, Caturano A, Vetrano E, Rinaldi L, Salvatore T, Ruggiero R, Rosaria Di Palo M, et al: Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study. Diabetes Res Clin Pract. 200:1106862023. View Article : Google Scholar : PubMed/NCBI | |
|
Russo V, Malvezzi Caracciolo D'Aquino M, Caturano A, Scognamiglio G, Pezzullo E, Fabiani D, Del Giudice C, Carbone A, Bottino R, Caso V, et al: Improvement of global longitudinal strain and myocardial work in type 2 diabetes patients on sodium-glucose cotransporter 2 inhibitors therapy. J Cardiovasc Pharmacol. 82:196–200. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Nagueh SF: Left ventricular diastolic function: Understanding pathophysiology, diagnosis, and prognosis with echocardiography. JACC Cardiovasc Imaging. 13:228–244. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ren C, Sun K, Zhang Y, Hu Y, Hu B, Zhao J, He Z, Ding R, Wang W and Liang C: Sodium-glucose CoTransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy. Front Pharmacol. 12:6641812021. View Article : Google Scholar : PubMed/NCBI | |
|
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, et al: Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 73:1931–1944. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA and Westenbrink BD: Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 21:862–873. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A and DeMarco VG: Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 16:92017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang N, Feng B, Ma X, Sun K, Xu G and Zhou Y: Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 18:1072019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF and Lee AS: The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 18:452019. View Article : Google Scholar : PubMed/NCBI | |
|
Lahnwong S, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, Chattipakorn SC and Chattipakorn N: Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovasc Diabetol. 19:912020. View Article : Google Scholar : PubMed/NCBI | |
|
Kräker K, Herse F, Golic M, Reichhart N, Crespo-Garcia S, Strauß O, Grune J, Kintscher U, Ebrahim M, Bader M, et al: Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes. Sci Rep. 10:140612020. View Article : Google Scholar : PubMed/NCBI | |
|
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Garcia-Ropero A, Ishikawa K, Watanabe S, Picatoste B, Vargas-Delgado AP, Flores-Umanzor EJ, Sanz J, et al: Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: A multimodality study. JACC Cardiovasc Imaging. 14:393–407. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lin YW, Chen CY, Shih JY, Cheng BC, Chang CP, Lin MT, Ho CH, Chen ZC, Fisch S and Chang WT: Dapagliflozin improves cardiac hemodynamics and mitigates arrhythmogenesis in mitral regurgitation-induced myocardial dysfunction. J Am Heart Assoc. 10:e0192742021. View Article : Google Scholar : PubMed/NCBI | |
|
Dini FL, Galeotti GG, Terlizzese G, Fabiani I, Pugliese NR and Rovai I: Left ventricular mass and thickness: Why does it matter? Heart Fail Clin. 15:159–166. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R and Utsunomiya K: Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 17:732018. View Article : Google Scholar : PubMed/NCBI | |
|
Nakamura M and Sadoshima J: Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 15:387–407. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL and Díez J: Increased collagen type I synthesis in patients with heart failure of hypertensive origin: Relation to myocardial fibrosis. Circulation. 110:1263–1268. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Frangogiannis NG: Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 65:70–99. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Frangogiannis NG: Cardiac fibrosis. Cardiovasc Res. 117:1450–1488. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Travers JG, Tharp CA, Rubino M and McKinsey TA: Therapeutic targets for cardiac fibrosis: From old school to next-gen. J Clin Invest. 132:e1485542022. View Article : Google Scholar : PubMed/NCBI | |
|
Aluja D, Delgado-Tomás S, Ruiz-Meana M, Barrabés JA and Inserte J: Calpains as potential therapeutic targets for myocardial hypertrophy. Int J Mol Sci. 23:41032022. View Article : Google Scholar : PubMed/NCBI | |
|
Yerra VG, Batchu SN, Kabir G, Advani SL, Liu Y, Siddiqi FS, Connelly KA and Advani A: Empagliflozin disrupts a Tnfrsf12a-mediated feed forward loop that promotes left ventricular hypertrophy. Cardiovasc Drugs Ther. 36:619–632. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Shi L, Zhu D, Wang S, Jiang A and Li F: Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload. Am J Hypertens. 32:452–459. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da Silva AA, Mouton A, Omoto ACM, Hall ME, Li J and Hall JE: Direct Cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure. J Am Heart Assoc. 10:e0182982021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Luo H, Liang Y, Tang J and Shu Y: Dapagliflozin ameliorates STZ-induced cardiac hypertrophy in type 2 diabetic rats by inhibiting the calpain-1 expression and nuclear transfer of NF-kappaB. Comput Math Methods Med. 2022:32930542022.PubMed/NCBI | |
|
Wang J, Huang X, Liu H, Chen Y, Li P, Liu L, Li J, Ren Y, Huang J, Xiong E, et al: Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function. Oxid Med Cell Longev. 2022:11224942022.PubMed/NCBI | |
|
Kimura T, Nakamura K, Miyoshi T, Yoshida M, Akazawa K, Saito Y, Akagi S, Ohno Y, Kondo M, Miura D, et al: Inhibitory effects of tofogliflozin on cardiac hypertrophy in dahl salt-sensitive and salt-resistant rats fed a high-fat diet. Int Heart J. 60:728–735. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh PL, Chu PM, Cheng HC, Huang YT, Chou WC, Tsai KL and Chan SH: Dapagliflozin mitigates doxorubicin-caused myocardium damage by regulating AKT-mediated oxidative stress, cardiac remodeling, and inflammation. Int J Mol Sci. 23:101462022. View Article : Google Scholar : PubMed/NCBI | |
|
Asensio Lopez MDC, Lax A, Hernandez Vicente A, Saura Guillen E, Hernandez-Martinez A, Fernandez Del Palacio MJ, Bayes-Genis A and Pascual Figal DA: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Sci Rep. 10:135532020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, Xu S, Xu Y, Hwa J, Li J, et al: Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 13:336–359. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Crow MT, Mani K, Nam YJ and Kitsis RN: The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res. 95:957–970. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Del Re DP, Amgalan D, Linkermann A, Liu Q and Kitsis RN: Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 99:1765–1817. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Abbate A, Bussani R, Amin MS, Vetrovec GW and Baldi A: Acute myocardial infarction and heart failure: Role of apoptosis. Int J Biochem Cell Biol. 38:1834–1840. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Wu M, Xu J, Xu B and Kang L: Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice. Eur J Pharm Sci. 161:1057882021. View Article : Google Scholar : PubMed/NCBI | |
|
Long Q, Li L, Yang H, Lu Y, Yang H, Zhu Y, Tang Y, Liu C and Yuan J: SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol. 110:1090242022. View Article : Google Scholar : PubMed/NCBI | |
|
El-Sayed N, Mostafa YM, AboGresha NM, Ahmed AAM, Mahmoud IZ and El-Sayed NM: Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats. Chem Biol Interact. 347:1096172021. View Article : Google Scholar : PubMed/NCBI | |
|
Fan ZG, Xu Y, Chen X, Ji MY and Ma GS: Appropriate dose of dapagliflozin improves cardiac outcomes by normalizing mitochondrial fission and reducing cardiomyocyte apoptosis after acute myocardial infarction. Drug Des Devel Ther. 16:2017–2030. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chang WT, Shih JY, Lin YW, Chen ZC, Kan WC, Lin TH and Hong CS: Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3. Arch Toxicol. 96:2021–2032. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ren FF, Xie ZY, Jiang YN, Guan X, Chen QY, Lai TF and Li L: Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin. 43:1721–1732. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zein L, Fulda S, Kögel D and van Wijk SJL: Organelle-specific mechanisms of drug-induced autophagy-dependent cell death. Matrix Biol. 100-101:54–64. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Liu J, Huang Y, Chang JYF, Liu L, McKeehan WL, Martin JF and Wang F: FRS2α-mediated FGF signals suppress premature differentiation of cardiac stem cells through regulating autophagy activity. Circ Res. 110:e29–e39. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Morales PE, Arias-Durán C, Ávalos-Guajardo Y, Aedo G, Verdejo HE, Parra V and Lavandero S: Emerging role of mitophagy in cardiovascular physiology and pathology. Mol Aspects Med. 71:1008222020. View Article : Google Scholar : PubMed/NCBI | |
|
Gatica D, Chiong M, Lavandero S and Klionsky DJ: Molecular mechanisms of autophagy in the cardiovascular system. Circ Res. 116:456–467. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M, Omiya S, Mizote I, Matsumura Y, Asahi M, et al: The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med. 13:619–624. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Munasinghe PE, Riu F, Dixit P, Edamatsu M, Saxena P, Hamer NS, Galvin IF, Bunton RW, Lequeux S, Jones G, et al: Type-2 diabetes increases autophagy in the human heart through promotion of Beclin-1 mediated pathway. Int J Cardiol. 202:13–20. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shirakabe A, Zhai P, Ikeda Y, Saito T, Maejima Y, Hsu CP, Nomura M, Egashira K, Levine B and Sadoshima J: Drp1-dependent mitochondrial autophagy plays a protective role against pressure overload-induced mitochondrial dysfunction and heart failure. Circulation. 133:1249–1263. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nishida K and Otsu K: Autophagy during cardiac remodeling. J Mol Cell Cardiol. 95:11–18. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nah J, Zhai P, Huang CY, Fernández ÁF, Mareedu S, Levine B and Sadoshima J: Upregulation of Rubicon promotes autosis during myocardial ischemia/reperfusion injury. J Clin Invest. 130:2978–2991. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda S, Zablocki D and Sadoshima J: The role of autophagy in death of cardiomyocytes. J Mol Cell Cardiol. 165:1–8. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Gatica D, Chiong M, Lavandero S and Klionsky DJ: The role of autophagy in cardiovascular pathology. Cardiovasc Res. 118:934–950. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang CY, Chen CC, Lin MH, Su HT, Ho MY, Yeh JK, Tsai ML, Hsieh IC and Wen MS: TLR9 binding to Beclin 1 and mitochondrial SIRT3 by a sodium-glucose co-transporter 2 inhibitor protects the heart from doxorubicin toxicity. Biology (Basel). 9:3692020.PubMed/NCBI | |
|
Deng R, Jiang K, Chen F, Miao Y, Lu Y, Su F, Liang J, Qian J, Wang D, Xiang Y and Shen L: Novel cardioprotective mechanism for empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia. Biomed Pharmacother. 154:1136062022. View Article : Google Scholar : PubMed/NCBI | |
|
Kang R, Zeh HJ, Lotze MT and Tang D: The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 18:571–580. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang CC, Li Y, Qian XQ, Zhao H, Wang D, Zuo GX and Wang K: Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. J Drug Target. 30:858–872. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Aragón-Herrera A, Feijóo-Bandín S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, Costa Pereira TM, Garcia-Caballero T, Rodriguez-Segade S, Rodriguez J, et al: Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 170:1136772019. View Article : Google Scholar : PubMed/NCBI | |
|
Ma H and Ma Y: Dapagliflozin inhibits ventricular remodeling in heart failure rats by activating autophagy through AMPK/mTOR pathway. Comput Math Methods Med. 2022:62602022022. View Article : Google Scholar : PubMed/NCBI | |
|
Yu YW, Que JQ, Liu S, Huang KY, Qian L, Weng YB, Rong FN, Wang L, Zhou YY, Xue YJ and Ji KT: Sodium-glucose co-transporter-2 inhibitor of dapagliflozin attenuates myocardial ischemia/reperfusion injury by limiting NLRP3 inflammasome activation and modulating autophagy. Front Cardiovasc Med. 8:7682142022. View Article : Google Scholar : PubMed/NCBI | |
|
Qin Y, Qiao Y, Wang D, Tang C and Yan G: Ferritinophagy and ferroptosis in cardiovascular disease: Mechanisms and potential applications. Biomed Pharmacother. 141:1118722021. View Article : Google Scholar : PubMed/NCBI | |
|
Tang D, Chen X, Kang R and Kroemer G: Ferroptosis: molecular mechanisms and health implications. Cell Res. 31:107–125. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Huang X, Song Y, Wei L, Guo J, Xu W and Li M: The emerging roles of ferroptosis in organ fibrosis and its potential therapeutic effect. Int Immunopharmacol. 116:1098122023. View Article : Google Scholar : PubMed/NCBI | |
|
Feng Y, Madungwe NB, Imam Aliagan AD, Tombo N and Bopassa JC: Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels. Biochem Biophys Res Commun. 520:606–611. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fang X, Wang H, Han D, Xie E, Yang X, Wei J, Gu S, Gao F, Zhu N, Yin X, et al: Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci USA. 116:2672–2680. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Baba Y, Higa JK, Shimada BK, Horiuchi KM, Suhara T, Kobayashi M, Woo JD, Aoyagi H, Marh KS, Kitaoka H and Matsui T: Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. Am J Physiol Heart Circ Physiol. 314:H659–H668. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bai T, Li M, Liu Y, Qiao Z and Wang Z: Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. Free Radic Biol Med. 160:92–102. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Xu S, Zhao C and Liu B: Role of TLR4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure. Biochem Biophys Res Commun. 516:37–43. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ma S, He LL, Zhang GR, Zuo QJ, Wang ZL, Zhai JL, Zhang TT, Wang Y, Ma HJ and Guo YF: Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction. Naunyn Schmiedebergs Arch Pharmacol. 395:945–962. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Chen X, Zhou W, Men H, Bao T, Sun Y, Wang Q, Tan Y, Keller BB, Tong Q, et al: Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways. Acta Pharm Sin B. 12:708–722. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Du S, Shi H, Xiong L, Wang P and Shi Y: Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy. Front Endocrinol (Lausanne). 13:10116692022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Lu J, Wang Y, Sun P, Gao T, Xu N, Zhang Y and Xie W: Canagliflozin attenuates lipotoxicity in cardiomyocytes by inhibiting inflammation and ferroptosis through activating AMPK pathway. Int J Mol Sci. 24:8582023. View Article : Google Scholar : PubMed/NCBI | |
|
Min J, Wu L, Liu Y, Song G, Deng Q, Jin W, Yu W, Abudureyimu M, Pei Z and Ren J: Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci. 312:1212072023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Zhang Y, Wang Z, Tan M, Lin J, Qian X, Li H and Jiang T: Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition. Front Pharmacol. 14:10782052023. View Article : Google Scholar : PubMed/NCBI | |
|
Aimo A, Castiglione V, Borrelli C, Saccaro LF, Franzini M, Masi S, Emdin M and Giannoni A: Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 27:494–510. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Halade GV and Lee DH: Inflammation and resolution signaling in cardiac repair and heart failure. EBioMedicine. 79:1039922022. View Article : Google Scholar : PubMed/NCBI | |
|
Prabhu SD and Frangogiannis NG: The biological basis for cardiac repair after myocardial infarction: From inflammation to fibrosis. Circ Res. 119:91–112. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Timmers L, Pasterkamp G, de Hoog VC, Arslan F, Appelman Y and de Kleijn DPV: The innate immune response in reperfused myocardium. Cardiovasc Res. 94:276–283. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schroder K and Tschopp J: The inflammasomes. Cell. 140:821–832. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Frieler RA and Mortensen RM: Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. 131:1019–1030. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Haudek SB, Taffet GE, Schneider MD and Mann DL: TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest. 117:2692–2701. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ing DJ, Zang J, Dzau VJ, Webster KA and Bishopric NH: Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res. 84:21–33. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS and Brower GL: Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 56:225–231. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG and Mann DL: Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 104:826–831. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Saxena A, Chen W, Su Y, Rai V, Uche OU, Li N and Frangogiannis NG: IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium. J Immunol. 191:4838–4848. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, Wen WF, Wan CH, Wu XM, Chang YY, et al: IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res. 114:690–702. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Didion SP, Kinzenbaw DA, Schrader LI, Chu Y and Faraci FM: Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. Hypertension. 54:619–624. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Szalay G, Sauter M, Hald J, Weinzierl A, Kandolf R and Klingel K: Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders. Am J Pathol. 169:2085–2093. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kolijn D, Pabel S, Tian Y, Lódi M, Herwig M, Carrizzo A, Zhazykbayeva S, Kovács A, Fülöp GÁ, Falcão-Pires I, et al: Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovasc Res. 117:495–507. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yan P, Song X, Tran J, Zhou R, Cao X, Zhao G and Yuan H: Dapagliflozin alleviates coxsackievirus B3-induced acute viral myocarditis by regulating the macrophage polarization through Stat3-related pathways. Inflammation. 45:2078–2090. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Faridvand Y, Nemati M, Zamani-Gharehchamani E, Nejabati HR, Zamani ARN, Nozari S, Safaie N, Nouri M and Jodati A: Dapagliflozin protects H9c2 cells against injury induced by lipopolysaccharide via suppression of CX3CL1/CX3CR1 axis and NF-κB activity. Curr Mol Pharmacol. 15:862–869. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Pinar AA, Scott TE, Huuskes BM, Tapia Cáceres FE, Kemp-Harper BK and Samuel CS: Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacol Ther. 209:1075112020. View Article : Google Scholar : PubMed/NCBI | |
|
Toldo S and Abbate A: The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 15:203–214. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Suetomi T, Willeford A, Brand CS, Cho Y, Ross RS, Miyamoto S and Brown JH: Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca2+/calmodulin-dependent protein kinase II δ signaling in cardiomyocytes are essential for adverse cardiac remodeling. Circulation. 138:2530–2544. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sokolova M, Ranheim T, Louwe MC, Halvorsen B, Yndestad A and Aukrust P: NLRP3 inflammasome: A novel player in metabolically induced inflammation-potential influence on the myocardium. J Cardiovasc Pharmacol. 74:276–284. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Y, Bajaj M, Yang HC, Perez-Polo JR and Birnbaum Y: SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 31:119–132. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Tran D, Yang HC, Nylander S, Birnbaum Y and Ye Y: Dapagliflozin and ticagrelor have additive effects on the attenuation of the activation of the NLRP3 inflammasome and the progression of diabetic cardiomyopathy: An AMPK-mTOR interplay. Cardiovasc Drugs Ther. 34:443–461. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M, Canale ML, et al: The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 20:1502021. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J, Xu J, Tan X, Li D, Yao D, Xu B and Lei Y: Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation. Naunyn Schmiedebergs Arch Pharmacol. 396:1461–1470. 2023.PubMed/NCBI | |
|
Pullen AB, Jadapalli JK, Rhourri-Frih B and Halade GV: Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease. Heart Fail Rev. 25:381–391. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee TM, Chang NC and Lin SZ: Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 104:298–310. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chelko SP, Asimaki A, Lowenthal J, Bueno-Beti C, Bedja D, Scalco A, Amat-Alarcon N, Andersen P, Judge DP, Tung L and Saffitz JE: Therapeutic modulation of the immune response in arrhythmogenic cardiomyopathy. Circulation. 140:1491–1505. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Z, Li T, Xian J, Chen J, Huang Y, Zhang Q, Lin X, Lu H and Lin Y: SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2alpha signaling pathway in arrhythmogenic cardiomyopathy. FASEB J. 36:e224102022. View Article : Google Scholar : PubMed/NCBI | |
|
Salvatore T, Galiero R, Caturano A, Vetrano E, Rinaldi L, Coviello F, Di Martino A, Albanese G, Colantuoni S, Medicamento G, et al: Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes. Biomolecules. 12:1762022. View Article : Google Scholar : PubMed/NCBI | |
|
Gordon M, Meagher P and Connelly KA: Effect of empagliflozin and liraglutide on the nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 inflammasome in a rodent model of type 2 diabetes mellitus. Can J Diabetes. 45:553–556. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Michaeloudes C, Abubakar-Waziri H, Lakhdar R, Raby K, Dixey P, Adcock IM, Mumby S, Bhavsar PK and Chung KF: Molecular mechanisms of oxidative stress in asthma. Mol Aspects Med. 85:1010262022. View Article : Google Scholar : PubMed/NCBI | |
|
Weissman D and Maack C: Redox signaling in heart failure and therapeutic implications. Free Radic Biol Med. 171:345–364. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Perino A, Ghigo A, Hirsch E and Shah AM: NADPH oxidases in heart failure: Poachers or gamekeepers? Antioxid Redox Signal. 18:1024–1041. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Burgoyne JR, Mongue-Din H, Eaton P and Shah AM: Redox signaling in cardiac physiology and pathology. Circ Res. 111:1091–1106. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
van der Pol A, van Gilst WH, Voors AA and van der Meer P: Treating oxidative stress in heart failure: Past, present and future. Eur J Heart Fail. 21:425–435. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li A, Zheng N and Ding X: Mitochondrial abnormalities: A hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress. Heart Fail Rev. 27:1387–1394. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Xing YJ, Liu BH, Wan SJ, Cheng Y, Zhou SM, Sun Y, Yao XM, Hua Q, Meng XJ, Cheng JH, et al: A SGLT2 inhibitor dapagliflozin alleviates diabetic cardiomyopathy by suppressing high glucose-induced oxidative stress in vivo and in vitro. Front Pharmacol. 12:7081772021. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Flynn ER, do Carmo JM, Wang Z, da Silva AA, Mouton AJ, Omoto ACM, Hall ME and Hall JE: Direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure. Front Cardiovasc Med. 9:8592532022. View Article : Google Scholar : PubMed/NCBI | |
|
Sun X, Han F, Lu Q, Li X, Ren D, Zhang J, Han Y, Xiang YK and Li J: Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice. Diabetes. 69:1292–1305. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bugga P, Mohammed SA, Alam MJ, Katare P, Meghwani H, Maulik SK, Arava S and Banerjee SK: Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress. Life Sci. 307:1208622022. View Article : Google Scholar : PubMed/NCBI | |
|
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS and Stanley WC: Myocardial fatty acid metabolism in health and disease. Physiol Rev. 90:207–258. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Taegtmeyer H, Sen S and Vela D: Return to the fetal gene program: A suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci. 1188:191–198. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ingwall JS: Energy metabolism in heart failure and remodelling. Cardiovasc Res. 81:412–419. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rosca MG, Tandler B and Hoppel CL: Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol. 55:31–41. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg C, Zaugg M and Lopaschuk GD: Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail. 6:1039–1048. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
De Jong KA and Lopaschuk GD: Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Can J Cardiol. 33:860–871. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kolwicz SC Jr, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE and Tian R: Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res. 111:728–738. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Choi YS, de Mattos ABM, Shao D, Li T, Nabben M, Kim M, Wang W, Tian R and Kolwicz SC Jr: Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion. J Mol Cell Cardiol. 100:64–71. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chess DJ, Lei B, Hoit BD, Azimzadeh AM and Stanley WC: Effects of a high saturated fat diet on cardiac hypertrophy and dysfunction in response to pressure overload. J Card Fail. 14:82–88. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Trang NN, Chung CC, Lee TW, Cheng WL, Kao YH, Huang SY, Lee TI and Chen YJ: Empagliflozin and liraglutide differentially modulate cardiac metabolism in diabetic cardiomyopathy in rats. Int J Mol Sci. 22:11772021. View Article : Google Scholar : PubMed/NCBI | |
|
Jia G, DeMarco VG and Sowers JR: Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 12:144–153. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lai J and Chen C: The role of epoxyeicosatrienoic acids in cardiac remodeling. Front Physiol. 12:6424702021. View Article : Google Scholar : PubMed/NCBI | |
|
Shi W, Xin Q, Yuan R, Yuan Y, Cong W and Chen K: Neovascularization: The main mechanism of MSCs in ischemic heart disease therapy. Front Cardiovasc Med. 8:6333002021. View Article : Google Scholar : PubMed/NCBI | |
|
Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shu HY, Peng YZ, Hang WJ, Zhang M, Shen L, Wang DW and Zhou N: Trimetazidine enhances myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice through directly activating Akt and promoting the binding of HSF1 to VEGF-A promoter. Acta Pharmacol Sin. 43:2550–2561. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ni Y, Deng J, Bai H, Liu C, Liu X and Wang X: CaMKII inhibitor KN-93 impaired angiogenesis and aggravated cardiac remodelling and heart failure via inhibiting NOX2/mtROS/p-VEGFR2 and STAT3 pathways. J Cell Mol Med. 26:312–325. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Blom JN, Wang X, Lu X, Kim MY, Wang G and Feng Q: Inhibition of intraflagellar transport protein-88 promotes epithelial-to-mesenchymal transition and reduces cardiac remodeling post-myocardial infarction. Eur J Pharmacol. 933:1752872022. View Article : Google Scholar : PubMed/NCBI | |
|
Wei T, Huang G, Gao J, Huang C, Sun M, Wu J, Bu J and Shen W: Sirtuin 3 deficiency accelerates hypertensive cardiac remodeling by impairing angiogenesis. J Am Heart Assoc. 6:e0061142017. View Article : Google Scholar : PubMed/NCBI | |
|
Gogiraju R, Hubert A, Fahrer J, Straub BK, Brandt M, Wenzel P, Münzel T, Konstantinides S, Hasenfuss G and Schäfer K: Endothelial leptin receptor deletion promotes cardiac autophagy and angiogenesis following pressure overload by suppressing Akt/mTOR signaling. Circ Heart Fail. 12:e0056222019. View Article : Google Scholar : PubMed/NCBI | |
|
Gu J, Wang S, Guo H, Tan Y, Liang Y, Feng A, Liu Q, Damodaran C, Zhang Z, Keller BB, et al: Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis. Cell Death Dis. 9:822018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou H, Wang S, Zhu P, Hu S, Chen Y and Ren J: Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 15:335–346. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nugrahaningrum DA, Marcelina O, Liu C, Wu S and Kasim V: Dapagliflozin promotes neovascularization by improving paracrine function of skeletal muscle cells in diabetic hindlimb ischemia mice through PHD2/HIF-1α axis. Front Pharmacol. 11:11042020. View Article : Google Scholar : PubMed/NCBI | |
|
Nakao M, Shimizu I, Katsuumi G, Yoshida Y, Suda M, Hayashi Y, Ikegami R, Hsiao YT, Okuda S, Soga T and Minamino T: Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload. Sci Rep. 11:183842021. View Article : Google Scholar : PubMed/NCBI | |
|
Zou R, Shi W, Qiu J, Zhou N, Du N, Zhou H, Chen X and Ma L: Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis. Cardiovasc Diabetol. 21:1062022. View Article : Google Scholar : PubMed/NCBI | |
|
Ma L, Zou R, Shi W, Zhou N, Chen S, Zhou H, Chen X and Wu Y: SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways. Theranostics. 12:5034–5050. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Guo H, Yu X, Liu Y, Paik DT, Justesen JM, Chandy M, Jahng JWS, Zhang T, Wu W, Rwere F, et al: SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant. Sci Transl Med. 15:eabp99522023. View Article : Google Scholar : PubMed/NCBI | |
|
Cai C, Guo Z, Chang X, Li Z, Wu F, He J, Cao T, Wang K, Shi N, Zhou H, et al: Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKalpha1/ULK1/FUNDC1/mitophagy pathway. Redox Biol. 52:1022882022. View Article : Google Scholar : PubMed/NCBI | |
|
Hanna A and Frangogiannis NG: The role of the TGF-beta superfamily in myocardial infarction. Front Cardiovasc Med. 6:1402019. View Article : Google Scholar : PubMed/NCBI | |
|
Tarbit E, Singh I, Peart JN and Rose'Meyer RB: Biomarkers for the identification of cardiac fibroblast and myofibroblast cells. Heart Fail Rev. 24:1–15. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, et al: SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 18:152019. View Article : Google Scholar : PubMed/NCBI | |
|
Humeres C, Shinde AV, Hanna A, Alex L, Hernández SC, Li R, Chen B, Conway SJ and Frangogiannis NG: Smad7 effects on TGF-β and ErbB2 restrain myofibroblast activation and protect from postinfarction heart failure. J Clin Invest. 132:e1469262022. View Article : Google Scholar : PubMed/NCBI | |
|
Daud E, Ertracht O, Bandel N, Moady G, Shehadeh M, Reuveni T and Atar S: The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats. Cardiovasc Diabetol. 20:1322021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Lin X, Chu Y, Chen X, Du H, Zhang H, Xu C, Xie H, Ruan Q, Lin J, et al: Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling. Cardiovasc Diabetol. 20:1212021. View Article : Google Scholar : PubMed/NCBI | |
|
Qi H, Liu Y, Li S, Chen Y, Li L, Cao Y, E M, Shi P, Song C, Li B and Sun H: Activation of AMPK attenuated cardiac fibrosis by inhibiting CDK2 via p21/p27 and miR-29 family pathways in rats. Mol Ther Nucleic Acids. 8:277–290. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hinson JT, Chopra A, Lowe A, Sheng CC, Gupta RM, Kuppusamy R, O'Sullivan J, Rowe G, Wakimoto H, Gorham J, et al: Integrative analysis of PRKAG2 cardiomyopathy iPS and microtissue models identifies AMPK as a regulator of metabolism, survival, and fibrosis. Cell Rep. 17:3292–3304. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tian J, Zhang M, Suo M, Liu D, Wang X, Liu M, Pan J, Jin T and An F: Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats. J Cell Mol Med. 25:7642–7659. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Yang Q, Bai W, Yao W, Liu L, Xing Y, Meng C, Qi P, Dang Y and Qi X: Dapagliflozin attenuates myocardial fibrosis by inhibiting the TGF-β1/Smad signaling pathway in a normoglycemic rabbit model of chronic heart failure. Front Pharmacol. 13:8731082022. View Article : Google Scholar : PubMed/NCBI | |
|
Hepworth EMW and Hinton SD: Pseudophosphatases as regulators of MAPK signaling. Int J Mol Sci. 22:125952021. View Article : Google Scholar : PubMed/NCBI | |
|
Rose BA, Force T and Wang Y: Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiol Rev. 90:1507–1546. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Z, Sun J, Tong Q, Lin Q, Qian L, Park Y and Zheng Y: The role of ERK1/2 in the development of diabetic cardiomyopathy. Int J Mol Sci. 17:20012016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, Wang Y, Fu C, Jiang Y, He C and Wei Q: Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther. 7:782022. View Article : Google Scholar : PubMed/NCBI | |
|
Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev. 22:153–183. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Streicher JM, Ren S, Herschman H and Wang Y: MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res. 106:1434–1443. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Chen K, Zhuang Y, Huang Y, Sui Y, Zhang Y, Lv L and Zhang G: Paeoniflorin improves pressure overload-induced cardiac remodeling by modulating the MAPK signaling pathway in spontaneously hypertensive rats. Biomed Pharmacother. 111:695–704. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ren J, Zhang S, Kovacs A, Wang Y and Muslin AJ: Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. J Mol Cell Cardiol. 38:617–623. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Yang N, Zou C, Luo W, Xu D, Wang M, Wang Y, Wu G, Shan P and Liang G: Sclareol attenuates angiotensin II-induced cardiac remodeling and inflammation via inhibiting MAPK signaling. Phytother Res. 37:578–591. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Lin K, Yang N, Luo W, Qian JF, Zhu WW, Ye SJ, Yuan CX, Xu DY, Liang G, Huang WJ and Shan PR: Direct cardio-protection of dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling. Acta Pharmacol Sin. 43:2624–2635. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ and Pavletich NP: mTOR kinase structure, mechanism and regulation. Nature. 497:217–223. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Saxton RA and Sabatini DM: mTOR signaling in growth, metabolism, and disease. Cell. 169:361–371. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, Spetz JF, Um SH, Brown EJ, Cereghini S, Thomas G and Kozma SC: Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol. 24:9508–9516. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Murakami M, Ichisaka T, Maeda M, Oshiro N, Hara K, Edenhofer F, Kiyama H, Yonezawa K and Yamanaka S: mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol. 24:6710–6718. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ and Izumo S: Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 107:1664–1670. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Das A, Salloum FN, Filippone SM, Durrant DE, Rokosh G, Bolli R and Kukreja RC: Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling. Basic Res Cardiol. 110:312015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao X, Lu S, Nie J, Hu X, Luo W, Wu X, Liu H, Feng Q, Chang Z, Liu Y, et al: Phosphoinositide-dependent kinase 1 and mTORC2 synergistically maintain postnatal heart growth and heart function in mice. Mol Cell Biol. 34:1966–1975. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xia Y, Wen HY, Young ME, Guthrie PH, Taegtmeyer H and Kellems RE: Mammalian target of rapamycin and protein kinase A signaling mediate the cardiac transcriptional response to glutamine. J Biol Chem. 278:13143–13150. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sciarretta S, Volpe M and Sadoshima J: Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res. 114:549–564. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Moellmann J, Mann PA, Kappel BA, Kahles F, Klinkhammer BM, Boor P, Kramann R, Ghesquiere B, Lebherz C, Marx N and Lehrke M: The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis. Diabetes Obes Metab. 24:2263–2272. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Sciarretta S, Forte M, Frati G and Sadoshima J: New insights into the role of mTOR signaling in the cardiovascular system. Circ Res. 122:489–505. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Kundu M, Viollet B and Guan KL: AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 13:132–141. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Liu P, Feng X and Ma C: Salidroside suppressing LPS-induced myocardial injury by inhibiting ROS-mediated PI3K/Akt/mTOR pathway in vitro and in vivo. J Cell Mol Med. 21:3178–3189. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sun P, Wang Y, Ding Y, Luo J, Zhong J, Xu N, Zhang Y and Xie W: Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway. iScience. 24:1025212021. View Article : Google Scholar : PubMed/NCBI | |
|
Das S, Aiba T, Rosenberg M, Hessler K, Xiao C, Quintero PA, Ottaviano FG, Knight AC, Graham EL, Bostrom P, et al: Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation. 126:2208–2219. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lang F and Shumilina E: Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1. FASEB J. 27:3–12. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SG, Kim D, Lee JJ, Lee HJ, Moon RK, Lee YJ, Lee SJ, Lee OH, Kim C, Oh J, et al: Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling. BMC Med. 20:3092022. View Article : Google Scholar : PubMed/NCBI | |
|
Mascareno E, El-Shafei M, Maulik N, Sato M, Guo Y, Das DK and Siddiqui MA: JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation. 104:325–329. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty D, Šumová B, Mallano T, Chen CW, Distler A, Bergmann C, Ludolph I, Horch RE, Gelse K, Ramming A, et al: Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun. 8:11302017. View Article : Google Scholar : PubMed/NCBI | |
|
Sabe SA, Xu CM, Sabra M, Harris DD, Malhotra A, Aboulgheit A, Stanley M, Abid MR and Sellke FW: Canagliflozin improves myocardial perfusion, fibrosis, and function in a swine model of chronic myocardial ischemia. J Am Heart Assoc. 12:e0286232023. View Article : Google Scholar : PubMed/NCBI | |
|
Yu LM, Di WC, Dong X, Li Z, Zhang Y, Xue XD, Xu YL, Zhang J, Xiao X, Han JS, et al: Melatonin protects diabetic heart against ischemia-reperfusion injury, role of membrane receptor-dependent cGMP-PKG activation. Biochim Biophys Acta Mol Basis Dis. 1864:563–578. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mátyás C, Németh BT, Oláh A, Hidi L, Birtalan E, Kellermayer D, Ruppert M, Korkmaz-Icöz S, Kökény G, Horváth EM, et al: The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol. 14:1452015. View Article : Google Scholar : PubMed/NCBI | |
|
Xue M, Li T, Wang Y, Chang Y, Cheng Y, Lu Y, Liu X, Xu L, Li X, Yu X, et al: Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clin Sci (Lond). 133:1705–1720. 2019. View Article : Google Scholar : PubMed/NCBI |
